This is the first known human documented with a GLP2R‐deficient phenotype, resulting in clinical illness, which correlates with the findings in the GLP2R mouse knockout model and furthers our understanding of GLP2R and the action of teduglutide, a GLP2 analog used for the treatment of short bowel syndrome. This evidence concerns the gene GCG and short bowel syndrome.